KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other financing activities (2017 - 2025)

Amneal Pharmaceuticals has reported Other financing activities over the past 6 years, most recently at $73.2 million for Q3 2025.

  • Quarterly results put Other financing activities at $73.2 million for Q3 2025, changed N/A from a year ago — trailing twelve months through Sep 2025 was $235.6 million (up 45.09% YoY), and the annual figure for FY2023 was $162.4 million, up 9666.39%.
  • Other financing activities for Q3 2025 was $73.2 million at Amneal Pharmaceuticals, down from $161.9 million in the prior quarter.
  • Over the last five years, Other financing activities for AMRX hit a ceiling of $161.9 million in Q4 2023 and a floor of $41000.0 in Q3 2022.
  • Median Other financing activities over the past 3 years was $36.9 million (2023), compared with a mean of $58.9 million.
  • Peak annual rise in Other financing activities hit 1221.95% in 2023, while the deepest fall reached 1221.95% in 2023.
  • Amneal Pharmaceuticals' Other financing activities stood at $41000.0 in 2022, then soared by 394712.2% to $161.9 million in 2023, then plummeted by 54.76% to $73.2 million in 2025.
  • The last three reported values for Other financing activities were $73.2 million (Q3 2025), $161.9 million (Q4 2023), and $542000.0 (Q3 2023) per Business Quant data.